Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
- PMID: 31186119
- DOI: 10.1016/S0140-6736(19)31350-9
Which to choose, an oral or an injectable glucagon-like peptide-1 receptor agonist?
Comment on
-
Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.Lancet. 2019 Jul 6;394(10192):39-50. doi: 10.1016/S0140-6736(19)31271-1. Epub 2019 Jun 8. Lancet. 2019. PMID: 31186120 Clinical Trial.
Similar articles
-
Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.Curr Diabetes Rev. 2018;14(3):273-279. doi: 10.2174/1573399813666170414101450. Curr Diabetes Rev. 2018. PMID: 28413990 Review.
-
Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment: Glucagon-Like Peptide-1 Receptor Agonists.J Fam Pract. 2017 Oct;66(10 Suppl):S12-S16. J Fam Pract. 2017. PMID: 28991932
-
Effects of the glucagon-like peptide-1 receptor agonist liraglutide on 24-h ambulatory blood pressure in patients with type 2 diabetes and stable coronary artery disease: a randomized, double-blind, placebo-controlled, crossover study.J Hypertens. 2017 May;35(5):1070-1078. doi: 10.1097/HJH.0000000000001275. J Hypertens. 2017. PMID: 28129251 Clinical Trial.
-
A discrete-choice experiment to quantify patient preferences for frequency of glucagon-like peptide-1 receptor agonist injections in the treatment of type 2 diabetes.Curr Med Res Opin. 2016;32(2):251-62. doi: 10.1185/03007995.2015.1117433. Epub 2015 Nov 30. Curr Med Res Opin. 2016. PMID: 26549576
-
The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy.Adv Ther. 2017 Mar;34(3):638-657. doi: 10.1007/s12325-017-0491-1. Epub 2017 Feb 16. Adv Ther. 2017. PMID: 28210986 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
